Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality

Study based on nationwide Swedish registry data found use of low-dose aspirin linked to significantly lower risk of hepatocellular carcinoma (4 vs.8.3%; HR 0.69; 95% CI, 0.62-0.76) and lower liver-related mortality vs. no aspirin, without significantly higher risk of GI bleeding.

New England Journal of Medicine